Cervical Intraepithelial Neoplasia

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

1083%

Monoclonal Antibody

217%

+ 31 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

InnovaxChina - Haicang District

10 programs

Recombinant Human Papillomavirus BivalentPhase 41 trial

3 doses of HPV 16/18 bivalent vaccinePhase 3Vaccine

HPV VaccinePhase 3Vaccine

Nonavalent HPV vaccinePhase 3Vaccine

30μg HPVPhase 2

+5 more programs

Active Trials

NCT06243666Active Not Recruiting2,188Est. Dec 2026

NCT05426148Completed540Est. Apr 2021

ViiV HealthcareNC - Durham

6 programs

HPVPhase 4

GSK Biologicals' HPV-16/18 VaccinePhase 3Vaccine

HPV9 High formulationPhase 1/2

Safety data collectionN/A

cisplatinN/A

+1 more programs

Enterprise TherapeuticsUK - Brighton

8 programs

3 doses of HPV 16/18 bivalent vaccinePhase 3Vaccine1 trial

HPV VaccinePhase 3Vaccine1 trial

Nonavalent HPV vaccinePhase 3Vaccine1 trial

30μg HPVPhase 21 trial

3 doses of HPV 16/18 bivalent vaccineN/AVaccine1 trial

+3 more programs

Active Trials

NCT03206255Completed940Est. Aug 2018

NCT05045755Unknown1,339Est. Jan 2024

NCT04969445Unknown647Est. Jan 2024

+5 more trials

MSDIreland - Ballydine

2 programs

PembrolizumabPhase 2Monoclonal Antibody1 trial

GardasilPhase 11 trial

Active Trials

NCT01338051Completed642Est. Apr 2012

NCT04712851Recruiting25Est. Jan 2028

Sharp TherapeuticsPA - Pittsburgh

2 programs

PembrolizumabPhase 2Monoclonal Antibody

GardasilPhase 1

GenexineKorea - Seoul

2 programs

GX-188EPhase 21 trial

Active Trials

NCT02139267Completed72Est. Mar 2016

NCT02596243Unknown134Est. Aug 2018

BiocorpFrance - Issoire

1 program

Aminolaevulinic acidPhase 21 trial

Active Trials

NCT02631863Completed60Est. Nov 2018

Prevail TherapeuticsNY - New York

1 program

PemetrexedPhase 21 trial

Active Trials

NCT00190983Completed29Est. Oct 2007

Inovio PharmaceuticalsCA - San Diego

1 program

VGX 3100Phase 21 trial

Active Trials

NCT01304524Completed167Est. Apr 2015

Antiva BiosciencesCA - Redwood City

1 program

ABI-2280 Vaginal Tablet/InsertPhase 1/21 trial

Active Trials

NCT05502367Terminated44Est. Oct 2025

GSKLONDON, United Kingdom

6 programs

Safety data collectionN/A1 trial

cisplatinN/A1 trial

paclitaxelN/A1 trial

HPV9 High formulationPHASE_1_21 trial

GSK Biologicals' HPV-16/18 VaccinePHASE_3Vaccine1 trial

+1 more programs

Active Trials

NCT03438006Completed3,016Est. Dec 2020

NCT01345279Completed1Est. Jul 2009

NCT01160185Completed1Est. Jul 2009

+3 more trials

City TherapeuticsMA - Cambridge

1 program

Recombinant Human Papillomavirus BivalentN/A

Eli Lilly and CompanyINDIANAPOLIS, IN

1 program

PemetrexedPHASE_2

Biotest PharmaceuticalsGermany - Dreieich

1 program

SOR007PHASE_21 trial

Active Trials

NCT03143491Withdrawn0Est. Mar 2019

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

InnovaxRecombinant Human Papillomavirus Bivalent

GSKHPV

Enterprise TherapeuticsNonavalent HPV vaccine

Enterprise Therapeutics3 doses of HPV 16/18 bivalent vaccine

Enterprise TherapeuticsHPV Vaccine

GSKGSK Biologicals' HPV-16/18 Vaccine

MSDPembrolizumab

Biotest PharmaceuticalsSOR007

BiocorpAminolaevulinic acid

GenexineGX-188E

Inovio PharmaceuticalsVGX 3100

Enterprise Therapeutics30μg HPV

Prevail TherapeuticsPemetrexed

Antiva BiosciencesABI-2280 Vaginal Tablet/Insert

Showing 15 of 25 trials with date data

Clinical Trials (25)

Total enrollment: 38,478 patients across 25 trials

NCT05426148 InnovaxRecombinant Human Papillomavirus Bivalent

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Start: May 2020Est. completion: Apr 2021540 patients

Phase 4Completed

NCT03629886 GSKHPV

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

Start: Aug 2018Est. completion: Feb 20206,051 patients

Phase 4Completed

NCT04537156 Enterprise TherapeuticsNonavalent HPV vaccine

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Start: Sep 2020Est. completion: Dec 20279,327 patients

Phase 3Active Not Recruiting

NCT02562508 Enterprise Therapeutics3 doses of HPV 16/18 bivalent vaccine

A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Start: Dec 2015Est. completion: Aug 2016979 patients

Phase 3Completed

NCT01735006 Enterprise TherapeuticsHPV Vaccine

Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Start: Nov 2012Est. completion: Oct 20197,372 patients

Phase 3Completed

NCT00316706 GSKGSK Biologicals' HPV-16/18 Vaccine

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Start: Oct 2005Est. completion: Jan 20091,245 patients

Phase 3Completed

NCT04712851 MSDPembrolizumab

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Start: Jun 2021Est. completion: Jan 202825 patients

Phase 2Recruiting

NCT03143491 Biotest PharmaceuticalsSOR007

Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)

Start: Oct 2017Est. completion: Mar 20190

Phase 2Withdrawn

NCT02631863 BiocorpAminolaevulinic acid

Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)

Start: Mar 2016Est. completion: Nov 201860 patients

Phase 2Completed

NCT02596243 GenexineGX-188E

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

Start: Aug 2015Est. completion: Aug 2018134 patients

Phase 2Unknown

NCT02139267 GenexineGX-188E

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Start: Jul 2014Est. completion: Mar 201672 patients

Phase 2Completed

NCT01304524 Inovio PharmaceuticalsVGX 3100

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

Start: Apr 2011Est. completion: Apr 2015167 patients

Phase 2Completed

NCT01356823 Enterprise Therapeutics30μg HPV

Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Start: Mar 2011Est. completion: Oct 20131,600 patients

Phase 2Completed

NCT00190983 Prevail TherapeuticsPemetrexed

A Trial for Patients With Advanced/Recurrent Cervical Cancer

Start: Feb 2005Est. completion: Oct 200729 patients

Phase 2Completed

NCT05502367 Antiva BiosciencesABI-2280 Vaginal Tablet/Insert

A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia

Start: Sep 2022Est. completion: Oct 202544 patients

Phase 1/2Terminated

NCT05496231 GSKHPV9 High formulation

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Start: Aug 2022Est. completion: Feb 20241,080 patients

Phase 1/2Completed

NCT01338051 MSDGardasil

The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru

Start: May 2011Est. completion: Apr 2012642 patients

Phase 1Completed

NCT06243666 InnovaxRecombinant Human Papillomavirus Bivalent

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Start: Feb 2024Est. completion: Dec 20262,188 patients

N/AActive Not Recruiting

NCT05045755 Enterprise TherapeuticsRecombinant Human Papillomavirus Bivalent

The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Start: Apr 2021Est. completion: Jan 20241,339 patients

N/AUnknown

NCT04969445 Enterprise TherapeuticsRecombinant Human Papillomavirus Bivalent

The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Start: Mar 2021Est. completion: Jan 2024647 patients

N/AUnknown

NCT04704908 Enterprise TherapeuticsRecombinant Human Papillomavirus Bivalent

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Start: Feb 2021Est. completion: Dec 2023979 patients

N/AUnknown

NCT03438006 GSKSafety data collection

A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects

Start: May 2018Est. completion: Dec 20203,016 patients

N/ACompleted

NCT03206255 Enterprise Therapeutics3 doses of HPV 16/18 bivalent vaccine

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Start: Jul 2017Est. completion: Aug 2018940 patients

N/ACompleted

NCT01345279 GSKcisplatin

Indirect Comparison Topotecan Cervical Carcinoma

Start: Jun 2009Est. completion: Jul 20091 patients

N/ACompleted

NCT01160185 GSKpaclitaxel

Meta-analysis of Efficacy of Topotecan

Start: Jun 2009Est. completion: Jul 20091 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 38,478 patients

14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.